Capital Fund Management (CFM)’s NovoCure NVCR Stock Holding History

Capital Fund Management (CFM)’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,600	Closed	-$524K	–	2240
2024 Q4	$524K	Hold	17,600	–	–	﹤0.01%	1897
2024 Q3	$275K	Sell	17,600 -13,300	-43%	-$241K	﹤0.01%	1920
2024 Q2	$529K	Sell	30,900 -70,800	-70%	-$1.25M	﹤0.01%	1745
2024 Q1	$1.59M	Sell	101,700 -64,300	-39%	-$946K	﹤0.01%	1543
2023 Q4	$2.48M	Buy	166,000 +146,900	+769%	+$1.97M	0.01%	1432
2023 Q3	$308K	Buy	+19,100	New	+$551K	﹤0.01%	1864
2022 Q1	–	Sell	-17,500	Closed	-$1.31M	–	1685
2021 Q4	$1.31M	Sell	17,500 -700	-4%	-$70.3K	0.01%	1189
2021 Q3	$2.11M	Buy	+18,200	New	+$2.75M	0.02%	916
2021 Q1	–	Sell	-13,000	Closed	-$2.25M	–	1513
2020 Q4	$2.25M	Buy	+13,000	New	+$1.78M	0.02%	743
2020 Q1	–	Sell	-8,100	Closed	-$683K	–	1882
2019 Q4	$683K	Sell	8,100 -13,500	-63%	-$1.09M	0.01%	1257
2019 Q3	$1.61M	Buy	21,600 +1,800	+9%	+$144K	0.01%	861
2019 Q2	$1.25M	Buy	+19,800	New	+$1M	0.01%	946

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Capital Fund Management (CFM)'s NVCR Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its NovoCure (NVCR) stake by 96% in Q1 2026, buying an estimated $852K and bringing the position to 139,529 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #1502.

Capital Fund Management (CFM) first reported a position in NVCR in Q4 2019 and has held it in 12 quarters since. The position peaked at $4.29M in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Capital Fund Management (CFM) held 139,529 shares of NovoCure worth $1.52M as of Q1 2026.
Capital Fund Management (CFM) bought 68,243 NovoCure shares in Q1 2026, an estimated $852K.
NovoCure made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1502 holding.
Capital Fund Management (CFM) first reported a position in NovoCure in Q4 2019 and has held it in 12 quarters since.
Capital Fund Management (CFM)'s NovoCure position peaked at $4.29M in Q4 2020.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.